Synthetic lethal approaches to breast cancer therapy (Q37801265)

23 August 2017

Synthetic lethal approaches to breast cancer therapy (English)

1 reference

23 August 2017

1 reference

2

1 reference

23 August 2017

3

Alan Ashworth

1 reference

23 August 2017

1

Farah L Rehman

1 reference

PubMed ID

20956981

23 August 2017

language of work or name

English

0 references

publication date

19 October 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

12

1 reference

23 August 2017

718-724

1 reference

Oophorectomy for breast cancer: history revisited.

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

PARP inhibitor development for systemic cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Third consensus on medical treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

New approaches to molecular cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

A comprehensive catalogue of somatic mutations from a human cancer genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Signatures of mutation and selection in the cancer genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Biology-driven cancer drug development: back to the future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

A 2009 update on the treatment of patients with hormone receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

The development and clinical use of trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Perspectives on the development of a molecularly targeted agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Integrating genetic approaches into the discovery of anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Focus on recombinational DNA repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Basal-like breast cancer and the BRCA1 phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Platinum-based chemotherapy in triple-negative breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Tenets of PTEN tumor suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

PTEN: a new guardian of the genome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Essential role for nuclear PTEN in maintaining chromosomal integrity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Tiling path genomic profiling of grade 3 invasive ductal breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Key signalling nodes in mammary gland development and cancer: Myc.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Roles of small RNAs in tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.172

Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster

31 March 2020

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.

1 reference

12 December 2020

Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

1 reference

12 December 2020

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer

1 reference

12 December 2020

Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium

1 reference

12 December 2020

PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death

1 reference

12 December 2020

10.1038/NRCLINONC.2010.172

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20956981